RxDoctor Payments Data

Neena Grewal, MD

Internal Medicine · Stony Point, NYNPI 1366410938

Payments from drug & device makers

$8,154in general payments, 2019–2025

Across 215 payments — averaging $37.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$978
  • Boston Scientific$938
  • Boehringer Ingelheim$763
  • Novo Nordisk$527
  • Lilly USA, LLC$403
  • plus $3K from 20 others

What the payments were for

  • Food & beverage$8,135100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,154 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$193,173
Medicare patients
296
Services billed
2,073

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$47,790
FarxigaDapagliflozin Propanediol27$43,751
TradjentaLinagliptin30$39,026
Xigduo XrDapaglifloz Propaned/Metformin24$34,348
JardianceEmpagliflozin20$30,308
MounjaroTirzepatide21$28,111
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$26,561
JanumetSitagliptin Phos/Metformin Hcl15$24,621
Jentadueto XrLinagliptin/Metformin Hcl16$23,896
Janumet XrSitagliptin Phos/Metformin Hcl16$19,313
VascepaIcosapent Ethyl11$6,489
Levothyroxine Sodium319$6,194
Metoprolol Succinate246$4,664
Rosuvastatin Calcium339$4,626
Ezetimibe152$3,533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTradjenta, Jardiance, Jentadueto Xr$763$93,23066 claims
Novo NordiskOzempic$527$47,79023 claims
MerckJanumet, Janumet Xr$211$43,93431 claims
AstraZenecaFarxiga$2,025$43,75127 claims
Lilly USA, LLCMounjaro$403$28,11121 claims
GSKTrelegy Ellipta$978$26,56117 claims
AbbVieSynthroid$135$1,59025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Stony Point

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →